|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities (net of acquisition): | |||||
| Depreciation | |||||
| Stock issued for services and donations | |||||
| Stock issued for donations to medical research | |||||
| Stock issued for charitable donations | |||||
| Stock issued for directors fees related party | |||||
| Imputed interest on loan | |||||
| (Gain) loss on marketable securities | |||||
| Gain on debt conversion | |||||
| Gain on asset sales | |||||
| Debt foregivess | |||||
| Loss on marketable securities | |||||
| Impairment expense | |||||
| Change in operating assets and liabilities | |||||
| (Increase)/Decrease is prepaid expenses | |||||
| (Increase)/Decrease is accounts receivable | |||||
| (Increase)/Decrease is inventory | |||||
| Increase(Decrease) in accounts payable and accrued expenses | |||||
| Increase (decrease) in accounts payable and accrued expenses-officers and directors | |||||
| Increase in accrued interest payable | |||||
| Increase in accounts payable and accrued expenses-related parties | |||||
| Increase(Decrease) in accrued interest payable | |||||
| Net Cash Used in Operating Activities | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||
| Cash acquired in GTI acquisition | |||||
| Cash returned in acquisition reversal BEC | |||||
| Cash acquired in GTI acquisition from license acquisition | |||||
| Cash from sale of assets | |||||
| Cash acquired from BEC acquisition | |||||
| Cash paid for property and equipment | |||||
| Cash paid for other assets | |||||
| Net Cash Provided by (Used in) Investing Activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||
| Proceeds from issuance of common stock | |||||
| Proceeds from exercise of warrants | |||||
| Proceeds from subsidiary shareholder advance | |||||
| Proceeds fron note payable | |||||
| Proceeds received from (paid on) convertible debentures | |||||
| Proceeds received from / (paid on) convertible debentures | |||||
| Proceeds from warrants | |||||
| Payments to officers and directors | |||||
| Proceeds from officers and directors | |||||
| Net Cash Provided by Financing Activities | |||||
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | |||||
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | |||||
| CASH AND CASH EQUIVALENTS, END OF PERIOD | |||||
| NON-CASH INVESTING AND FINANCING ACTIVITIES: | |||||
| Stock issued and held in escrow for potential acquisitions | |||||
| Assets acquired from Bronx with share issuance | |||||
| Liabilities assumed from Bronx with share issuance | |||||
| Additions to ROU assets obtained from acquired operating lease liabilities | |||||
| Operating lease liabilities acquired from Bronx in acquisition | |||||
| Stock held in escrow | |||||
| Debt converted to stock | |||||
| Assets acquired from BEC with issuance of common stock | |||||
| Liabilities assumed from BEC with issuance of common stock | |||||
| Initial recognition of right of use asset and lease liability in acquisition of BEC | |||||
| Stock issued for asset acquisition | |||||
| Warrants issued as a dividend to shareholders | |||||
Loading...